Efficacy and Safety of Sarilumab in patients with COVID19 Pneumonia : A Randomized, Phase III Clinical Trial (SARTRE Study)
© 2021. The Author(s)..
INTRODUCTION: SARS-CoV-2 pneumonia is often associated with hyper-inflammation. The cytokine-storm-like is one of the targets of current therapies for coronavirus disease 2019 (COVID-19). High Interleukin-6 (IL6) blood levels have been identified in severe COVID-19 disease, but there are still uncertainties regarding the actual role of anti-IL6 antagonists in COVID-19 management. Our hypothesis was that the use of sarilumab plus corticosteroids at an early stage of the hyper-inflammatory syndrome would be beneficial and prevent progression to acute respiratory distress syndrome (ARDS).
METHODS: We randomly assigned (in a 1:1 ratio) COVID-19 pneumonia hospitalized patients under standard oxygen therapy and laboratory evidence of hyper-inflammation to receive sarilumab plus usual care (experimental group) or usual care alone (control group). Corticosteroids were given to all patients at a 1 mg/kg/day of methylprednisolone for at least 3 days. The primary outcome was the proportion of patients progressing to severe respiratory failure (defined as a score in the Brescia-COVID19 scale ≥ 3) up to day 15.
RESULTS: A total of 201 patients underwent randomization: 99 patients in the sarilumab group and 102 patients in the control group. The rate of patients progressing to severe respiratory failure (Brescia-COVID scale score ≥ 3) up to day 15 was 16.16% in the Sarilumab group versus 15.69% in the control group (RR 1.03; 95% CI 0.48-2.20). No relevant safety issues were identified.
CONCLUSIONS: In hospitalized patients with Covid-19 pneumonia, who were under standard oxygen therapy and who presented analytical inflammatory parameters, an early therapeutic intervention with sarilumab plus standard of care (including corticosteroids) was not shown to be more effective than current standard of care alone. The study was registered at EudraCT with number: 2020-002037-15.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Infectious diseases and therapy - 10(2021), 4 vom: 18. Dez., Seite 2735-2748 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID19 |
|---|
| Anmerkungen: |
Date Revised 08.11.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s40121-021-00543-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331984164 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331984164 | ||
| 003 | DE-627 | ||
| 005 | 20231225214657.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40121-021-00543-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1106.xml |
| 035 | |a (DE-627)NLM331984164 | ||
| 035 | |a (NLM)34658006 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sancho-López, Aránzazu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and Safety of Sarilumab in patients with COVID19 Pneumonia |b A Randomized, Phase III Clinical Trial (SARTRE Study) |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a INTRODUCTION: SARS-CoV-2 pneumonia is often associated with hyper-inflammation. The cytokine-storm-like is one of the targets of current therapies for coronavirus disease 2019 (COVID-19). High Interleukin-6 (IL6) blood levels have been identified in severe COVID-19 disease, but there are still uncertainties regarding the actual role of anti-IL6 antagonists in COVID-19 management. Our hypothesis was that the use of sarilumab plus corticosteroids at an early stage of the hyper-inflammatory syndrome would be beneficial and prevent progression to acute respiratory distress syndrome (ARDS) | ||
| 520 | |a METHODS: We randomly assigned (in a 1:1 ratio) COVID-19 pneumonia hospitalized patients under standard oxygen therapy and laboratory evidence of hyper-inflammation to receive sarilumab plus usual care (experimental group) or usual care alone (control group). Corticosteroids were given to all patients at a 1 mg/kg/day of methylprednisolone for at least 3 days. The primary outcome was the proportion of patients progressing to severe respiratory failure (defined as a score in the Brescia-COVID19 scale ≥ 3) up to day 15 | ||
| 520 | |a RESULTS: A total of 201 patients underwent randomization: 99 patients in the sarilumab group and 102 patients in the control group. The rate of patients progressing to severe respiratory failure (Brescia-COVID scale score ≥ 3) up to day 15 was 16.16% in the Sarilumab group versus 15.69% in the control group (RR 1.03; 95% CI 0.48-2.20). No relevant safety issues were identified | ||
| 520 | |a CONCLUSIONS: In hospitalized patients with Covid-19 pneumonia, who were under standard oxygen therapy and who presented analytical inflammatory parameters, an early therapeutic intervention with sarilumab plus standard of care (including corticosteroids) was not shown to be more effective than current standard of care alone. The study was registered at EudraCT with number: 2020-002037-15 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID19 | |
| 650 | 4 | |a Corticosteroids | |
| 650 | 4 | |a IL6-inhibitors | |
| 650 | 4 | |a Randomized clinical trial | |
| 650 | 4 | |a Sarilumab | |
| 700 | 1 | |a Caballero-Bermejo, Antonio F |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Antorán, Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Múñez Rubio, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a García Gasalla, Mercedes |e verfasserin |4 aut | |
| 700 | 1 | |a Buades, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a González Rozas, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a López Veloso, María |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz Gómez, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Cuenca Abarca, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Durán Del Campo, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Ibáñez, Fátima |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz de Santiago, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Romero, Yolanda |e verfasserin |4 aut | |
| 700 | 1 | |a Calderón, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Pintos, Ilduara |e verfasserin |4 aut | |
| 700 | 1 | |a Ferre Beltrán, Adrián |e verfasserin |4 aut | |
| 700 | 1 | |a Centeno Soto, Gustavo |e verfasserin |4 aut | |
| 700 | 1 | |a Campos, José |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos Martínez, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Avendaño-Solá, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández Cruz, Ana |e verfasserin |4 aut | |
| 700 | 0 | |a SARTRE-Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Sancho-López, Aránzazu |e investigator |4 oth | |
| 700 | 1 | |a Caballero, Antonio F Bermejo |e investigator |4 oth | |
| 700 | 1 | |a Ruiz-Antorán, Belén |e investigator |4 oth | |
| 700 | 1 | |a Fernández-Cruz, Ana |e investigator |4 oth | |
| 700 | 1 | |a Múñez, Elena |e investigator |4 oth | |
| 700 | 1 | |a Ramos Martínez, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Avendaño-Solá, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Diago-Sempere, Elena |e investigator |4 oth | |
| 700 | 1 | |a Del Campo, Pedro Durán |e investigator |4 oth | |
| 700 | 1 | |a Ibáñez, Fátima |e investigator |4 oth | |
| 700 | 1 | |a de Santiago, Alberto Díaz |e investigator |4 oth | |
| 700 | 1 | |a Romero, Yolanda |e investigator |4 oth | |
| 700 | 1 | |a Parra, Jorge Calderón |e investigator |4 oth | |
| 700 | 1 | |a Pinto, Ilduara |e investigator |4 oth | |
| 700 | 1 | |a Centeno, Gustavo |e investigator |4 oth | |
| 700 | 1 | |a Payares, Concepción |e investigator |4 oth | |
| 700 | 1 | |a Ramírez-García, Almudena |e investigator |4 oth | |
| 700 | 1 | |a Javaloyes, Laura |e investigator |4 oth | |
| 700 | 1 | |a de la Encina Higuera, María |e investigator |4 oth | |
| 700 | 1 | |a Acero, Rocío Layunta |e investigator |4 oth | |
| 700 | 1 | |a Vicente, Laura |e investigator |4 oth | |
| 700 | 1 | |a Araque, Paloma Rodríguez |e investigator |4 oth | |
| 700 | 1 | |a Ussetti-Gil, Piedad |e investigator |4 oth | |
| 700 | 1 | |a de Molina, Rosa Malo |e investigator |4 oth | |
| 700 | 1 | |a Alonso, Andrea Trisan |e investigator |4 oth | |
| 700 | 1 | |a Falconés, Manuel Valle |e investigator |4 oth | |
| 700 | 1 | |a Montoya, Fernando |e investigator |4 oth | |
| 700 | 1 | |a JiménezJiménez, María Luisa |e investigator |4 oth | |
| 700 | 1 | |a Ferrer, Laura |e investigator |4 oth | |
| 700 | 1 | |a Ramos, Jorge |e investigator |4 oth | |
| 700 | 1 | |a Junco, Alejandro |e investigator |4 oth | |
| 700 | 1 | |a Campos, José |e investigator |4 oth | |
| 700 | 1 | |a Díaz, Alejandro Callejas |e investigator |4 oth | |
| 700 | 1 | |a de la Fuente Moral, Sara |e investigator |4 oth | |
| 700 | 1 | |a Laguna, Pedro |e investigator |4 oth | |
| 700 | 1 | |a Contreras, Gema Vázquez |e investigator |4 oth | |
| 700 | 1 | |a Serrano, Alejandro Muñoz |e investigator |4 oth | |
| 700 | 1 | |a Pérez, Isolina Baños |e investigator |4 oth | |
| 700 | 1 | |a Torres-Concha, Víctor Moreno |e investigator |4 oth | |
| 700 | 1 | |a Maroto, Alfonso Ángel-Moreno |e investigator |4 oth | |
| 700 | 1 | |a Hernández, Esther Montero |e investigator |4 oth | |
| 700 | 1 | |a Saíz, Mª Carmen Máinez |e investigator |4 oth | |
| 700 | 1 | |a Hernández, Mª Cruz Carreño |e investigator |4 oth | |
| 700 | 1 | |a de Benito, Rosa Muñoz |e investigator |4 oth | |
| 700 | 1 | |a Pita, Susana Mellor |e investigator |4 oth | |
| 700 | 1 | |a de Ureta, Pablo Tutor |e investigator |4 oth | |
| 700 | 1 | |a Pérez, Miriam Aguilar |e investigator |4 oth | |
| 700 | 1 | |a Nuevo, Gema Díaz |e investigator |4 oth | |
| 700 | 1 | |a Fadul, Christian García |e investigator |4 oth | |
| 700 | 1 | |a Chinarro, Beatriz Jara |e investigator |4 oth | |
| 700 | 1 | |a Hernández, Rosalía Laporta |e investigator |4 oth | |
| 700 | 1 | |a de la FuenteCarrasco, María Lázaro |e investigator |4 oth | |
| 700 | 1 | |a Gallo, Cristina López García |e investigator |4 oth | |
| 700 | 1 | |a Clemente, Patricia Mínguez |e investigator |4 oth | |
| 700 | 1 | |a Arca, Roberto Carabias |e investigator |4 oth | |
| 700 | 1 | |a IribarrenIribarren, Marta Erro |e investigator |4 oth | |
| 700 | 1 | |a Eisenhofer, Ane Andrés |e investigator |4 oth | |
| 700 | 1 | |a Yagüe, Itziar Diego |e investigator |4 oth | |
| 700 | 1 | |a VelascoVelasco, Ignacio Donate |e investigator |4 oth | |
| 700 | 1 | |a López, Gabriela Escudero |e investigator |4 oth | |
| 700 | 1 | |a Palomo, Esther Expósito |e investigator |4 oth | |
| 700 | 1 | |a Gómez, Amy Galán |e investigator |4 oth | |
| 700 | 1 | |a Prieto, Sonia García |e investigator |4 oth | |
| 700 | 1 | |a Irusta, Javier Gómez |e investigator |4 oth | |
| 700 | 1 | |a Abreu, Edith Vanessa Gutiérrez |e investigator |4 oth | |
| 700 | 1 | |a Martín, Isabel Gutiérrez |e investigator |4 oth | |
| 700 | 1 | |a Rojas, Ángela Gutiérrez |e investigator |4 oth | |
| 700 | 1 | |a Villanueva, Andrea Gutiérrez |e investigator |4 oth | |
| 700 | 1 | |a Jiménez, Jesús Herráiz |e investigator |4 oth | |
| 700 | 1 | |a Urbistondo, María Martínez |e investigator |4 oth | |
| 700 | 1 | |a Vara, Fernando Martínez |e investigator |4 oth | |
| 700 | 1 | |a Sánchez, Patricia Mills |e investigator |4 oth | |
| 700 | 1 | |a Vargas, Alberto Mora |e investigator |4 oth | |
| 700 | 1 | |a de la Torre, Ignacio Morrás |e investigator |4 oth | |
| 700 | 1 | |a Chica, Enrique Sánchez |e investigator |4 oth | |
| 700 | 1 | |a Alijo, Ángela Valencia |e investigator |4 oth | |
| 700 | 1 | |a Comendador, Jos Manuel Vázquez |e investigator |4 oth | |
| 700 | 1 | |a Milla, Ana Arias |e investigator |4 oth | |
| 700 | 1 | |a Núñez, Juan Antonio Vargas |e investigator |4 oth | |
| 700 | 1 | |a Martínez, Valentín Cuervas-Mons |e investigator |4 oth | |
| 700 | 1 | |a Cubero, Carmen |e investigator |4 oth | |
| 700 | 1 | |a Olleros, Celia Rodríguez |e investigator |4 oth | |
| 700 | 1 | |a Carral, Elvira Ramos |e investigator |4 oth | |
| 700 | 1 | |a Tung, Yale |e investigator |4 oth | |
| 700 | 1 | |a Gasalla, Mercedes García |e investigator |4 oth | |
| 700 | 1 | |a Beltrán, Adrián Ferré |e investigator |4 oth | |
| 700 | 1 | |a Bosch, Pere Ventayol |e investigator |4 oth | |
| 700 | 1 | |a Balaguer, Juana Maria Ferrer |e investigator |4 oth | |
| 700 | 1 | |a Serra, Francisca Artigues |e investigator |4 oth | |
| 700 | 1 | |a Pinheiro, Alfredo Manuel Santos |e investigator |4 oth | |
| 700 | 1 | |a Vilchez, Helem H Rueda |e investigator |4 oth | |
| 700 | 1 | |a Palomero, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Gómez, Ana Muñoz |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, Francisco Javier Teigell |e investigator |4 oth | |
| 700 | 1 | |a Guijarro, Elena García |e investigator |4 oth | |
| 700 | 1 | |a Sánchez, Francisco García |e investigator |4 oth | |
| 700 | 1 | |a Bermejo, José Antonio Melero |e investigator |4 oth | |
| 700 | 1 | |a González, María Mateos |e investigator |4 oth | |
| 700 | 1 | |a Sánchez, Aitor Olmo |e investigator |4 oth | |
| 700 | 1 | |a de la Sota, Juan Vicente |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d 2012 |g 10(2021), 4 vom: 18. Dez., Seite 2735-2748 |w (DE-627)NLM240483693 |x 2193-8229 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:4 |g day:18 |g month:12 |g pages:2735-2748 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40121-021-00543-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 4 |b 18 |c 12 |h 2735-2748 | ||